U.S. Markets closed

Halozyme announces positive CHMP opinion on Roche's Herceptin SC

Halozyme Therapeutics (HALO) announced that Roche (RHHBY) received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use for the subcutaneous formulation of Herceptin using Halozyme's recombinant human hyaluronidase for the treatment of patients with HER2-positive breast cancer in Europe.